Abstracts tagged "Vasculitis"

Abstract Number: 1641 • ACR Convergence 2021
Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review
Francis Lao¹, Cal Robinson², Megan Schlorff¹, Jocelyne Ewusie³, Karen Beattie¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²The Hospital for Sick Children, Hamilton, ON, Canada, ³St Joseph's Healthcare, Hamilton, ON, Canada
Background/Purpose: Kawasaki Disease (KD) is a common vasculitis of childhood, with an annual North American incidence of 20-26 per 100,000 children (< 5 years of…
Abstract Number: 0420 • ACR Convergence 2021
Development and Validation of a Simulation Model for Maintenance Treatment in ANCA-Associated Vasculitis
Zachary Wallace¹, John Stone², Hyon K. Choi³ and Emily Hyle⁴, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Lexington, MA, ⁴Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) care has evolved over the last two decades with several approaches to remission maintenance. However, these approaches have trade-offs regarding the…
Abstract Number: 1396 • ACR Convergence 2021
Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study
Matthew Koster¹, Cynthia Crowson², Rachel Giblon¹, Ali Duarte-Garcia¹, Jane Jaquith¹, Cornelia M. Weyand¹ and Kenneth Warrington³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, Minnesota
Background/Purpose: Pre-clinical giant cell arteritis (GCA) mouse models have demonstrated effective suppression of arterial wall lesional T-cells through inhibition of Janus kinase 3 (JAK3) and…
Abstract Number: 1720 • ACR Convergence 2021
Cervical Dysplasia and HPV Infection in Women with Vasculitis
Taylor Koenig¹, Ambra Burrell², Hilary Kleppel³, Ashlee Weaver⁴, Veronica Mruk⁵, Lynn Fussner¹, Salem Almaani⁶ and Alexa Meara¹, ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Division of Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Wright State University, Blacklick, OH, ⁴Ohio State University College of Medicine, Columbus, OH, ⁵Ohio State University / Nationwide Children's Hospital, Columbus, OH, ⁶Ohio State University Medical Center, Columbus, OH
Background/Purpose: The most common cause of cervical cancer is persistent human papillomavirus (HPV) infection in the cervical epithelium, causing precancerous cervical dysplasia and ultimately cervical…
Abstract Number: 0425 • ACR Convergence 2021
Diagnostic Accuracy of Muscle MRI for Muscular Vasculitis in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Pilot Study
Ryuta Inaba, Daisuke Waki, Keisuke Nishimura, Tomohiro Yoshida, Kaoru Mizukawa, Shintaro Yamamoto, Osamu Iri, Kohei Yo and Hiroyuki Murabe, Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan
Background/Purpose: Histopathologic confirmation is the golden standard for diagnosis of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), but sometimes can be difficult because of its invasion (e.g.…
Abstract Number: 1397 • ACR Convergence 2021
Treatment of Giant Cell Arteritis with Tocilizumab: A Retrospective Cohort Study of 119 Patients
jigisha rakholiya¹, Matthew Koster¹, Hannah Langenfeld¹, Cynthia Crowson², Andy Abril³, Pankaj Bansal⁴, Lester Mertz⁵, Alicia Rodriguez Pla⁶, Rahul Sehgal⁴, Benjamin Wang⁷ and Kenneth Warrington⁸, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Ponte Vedra Beach, FL, ⁴Mayo Clinic, Eau Claire, WI, ⁵Mayo Clinic Arizona, Scottsdale, AZ, ⁶Mayo Clinic in Arizona, Scottsdale, AZ, ⁷Mayo Clinic, Jacksonville, FL, ⁸Mayo Clinic, Rochester, Minnesota
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory condition of medium- and large-sized arteries. Prospective clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for…
Abstract Number: 1728 • ACR Convergence 2021
Takayasu’s Arteritis and Pregnancy: A Meta-analysis
Aine Gorman¹, Leah Rooney², Matthew Turk¹, Louise Moore³, Jared Bierbrier⁴, Celine O'Brien⁵, Anne Clohessy⁶, Eamonn Molloy⁷, Lorraine O Neill⁸, Fionnuala McAuliffe⁹ and Douglas Veale¹⁰, ¹St Vincents Hospital, Dublin, Ireland, ²St Vincent's University Hospital, Dublin, Ireland, ³Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, ⁴McMaster University, Hamilton, ON, Canada, ⁵Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, ⁶National Maternity Hopistal, Dublin, Ireland, ⁷St Vincent's Healthcare Group, Dublin, Ireland, ⁸St. Vincent's Hospital, Dublin, Ireland, ⁹National Maternity Hopsital Dublin, Dublin, Ireland, ¹⁰University College Dublin, Dublin, Ireland
Background/Purpose: Takayasu’s arteritis is a systemic autoimmune disease characterised by large vessel vasculitis. It usually affects women of childbearing age, with 90% of patients diagnosed…
Abstract Number: 0431 • ACR Convergence 2021
Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study
Eduardo Martin-Nares, Lilian Guadalupe Cano Cruz and Andrea Hinojosa-Azaola, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Hypertrophic pachymeningitis (HP) is an infrequent manifestation in autoimmune and non-autoimmune conditions. The differences in clinical characteristics and outcomes of ANCA-associated and non-immune-mediated HP…
Abstract Number: 1403 • ACR Convergence 2021
Giant Cell Arteritis Subtypes: Data from the ARTESER Registry
Eugenio De Miguel¹, Jesús T. Sánchez-Costa², Javier Narvaez³, Miguel Ángel gonzalez-Gay⁴, Noemí Garrido-Puñal⁵, Paula V. Estrada-Alarcon⁶, Rafael B. Melero-González⁷, Elisa Fernández-Fernández⁸, María T. Silva-Diaz⁹, Joaquín M. Belzunegui¹⁰, Clara Moriano¹¹, Julio Sánchez¹², Judit Lluch¹³, Itziar Calvo¹⁴, Vicente Aldasoro¹⁵, Leticia León-Mateos¹⁶, Javier Loricera García¹⁷, Alberto Ruíz-Román⁵, Cristina Valero-Martínez¹⁸, Patricia Moya¹⁹, Marina Tortosa-Cabañas²⁰, Vanessa A. Navarro-Angeles⁶, Carles Galisteo²¹, Anne Riveros-Frutos²², Jose A. Román-Ivorra²³, Selene Labrada-Arrabal²⁴, Margarida Vasques-Rocha²⁵, Carlota L. Iñiguez-Ubiaga²⁶, María García-González²⁷ and Ricardo Blanco²⁸, ¹Hospital Universitario La Paz, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁶Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁹Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ¹⁰Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ¹¹Hospital Universitario de León, León, Spain, ¹²Hospital Universitario 12 de Octubre, Madrid, Spain, ¹³Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁶Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁸Hospital Universitario de La Princesa, Madrid, Spain, ¹⁹Hospital Sant Pau, Barcelona, Spain, ²⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ²¹Hospital Universitari Parc Tauli, Saadell, Spain, ²²Hospital Germans Trias i Pujol, Badalona, Spain, ²³Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²⁴Hospital del Mar, Barcelona, Spain, ²⁵Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²⁶Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁷Hospital Universitario de Canarias, La Laguna, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis over 50 years of age. Classically, GCA was assimilated with the involvement of the…
Abstract Number: 1862 • ACR Convergence 2021
Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis
Kristina Wells¹, Fernanda Gutierrez-Rodrigues², Bhavisha Patel², Kaitlin Quinn³, Keith Sikora¹, Neal Young⁴ and Peter Grayson⁵, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institues of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Clonal hematopoiesis (CH) is a pre-malignant state characterized by somatic mutations in hematologic precursor cells in genes associated with myeloid malignancies. Incidence of CH…
Abstract Number: 0432 • ACR Convergence 2021
Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months
Allyson Egan¹, Pasupathy Sivasothy², Lisa Willcocks², Rachel Jones², Marcos Martinez Del Pero³ and David R.W. Jayne⁴, ¹Vasculitis and Lupus Centre, Cambridge University Hospital, University of Cambridge, London, United Kingdom, ²Vasculitis and Lupus Centre, Department of Medicine, Cambridge University Hospital, Cambridge, United Kingdom, ³Vasculitis and Lupus Centre, Cambridge University Hospital, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 1405 • ACR Convergence 2021
Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
Lara Sánchez-Bilbao¹, Javier Loricera¹, Santos Castañeda², Clara Moriano³, Javier Narvaez⁴, Vicente Aldasoro⁵, Olga Maíz⁶, Rafael Melero⁷, Juan Ignacio Villa⁸, Paloma Vela⁹, Susana Romero-Yuste¹⁰, José Luis Callejas¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Francisca Sivera¹⁴, Jesús Carlos Fernández-López¹⁵, Carles Galisteo¹⁶, Iván Ferraz-Amaro¹⁷, Juan Carlos Nieto¹⁸, Juan Ramón de Dios¹⁹, Julio Sánchez²⁰, Esther Fernández²¹, Isabel de la Morena²², Patricia Moya²³, Roser Solans-Laqué²⁴, Jose Luis Andreu²⁵, Marcelino Revenga²⁶, Eztizen Labrador²⁷, Andrea García-Valle²⁸, Adela Gallego²⁹, Carlota Iñíguez³⁰, Cristina Hidalgo³¹, Noemí Garrido-Puñal³², Ruth López-González³³, José Andrés Román-Ivorra³⁴, Sara Manrique Arija³⁵, Paz Collado³⁶, Enrique Raya¹¹, Francisco Navarro³⁷, Antoni Juan Mas³⁸, Carmen Ordas³⁹, Maria Dolors Boquet⁴⁰, Noelia Álvarez-Rivas⁴¹, Maria Luisa Velloso-Feijoo⁴², Cristina Campos-Fernández⁴³, Íñigo Rúa-Figueroa⁴⁴, Arantxa Conesa⁴⁵, Eva Salgado⁴⁶, Miguel Ángel gonzalez-Gay⁴⁷ and Ricardo Blanco⁴⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario de la Princesa, Madrid, Spain, ³Hospital Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, Spain, ⁷Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ⁸Hospital Sierrallana, Torrelavega, Spain, ⁹Hospital General Universitario de Alicante, Alicante, Spain, ¹⁰Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de Basurto, Bilbao, Spain, ¹⁴Hospital Universitario de Elda, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, A Coruña, Spain, ¹⁶Hospital Universitari Parc Tauli, Saadell, Spain, ¹⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁸Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁹Hospital Universitario de Araba, Mondragón, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²²Hospital Clínico Universitario de Valencia, Valencia, Spain, ²³Hospital Sant Pau, Barcelona, Spain, ²⁴Hospital Vall d'Hebron, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Hospital San Pedro, Logroño, La Rioja, Spain, ²⁸Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, ²⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ³⁰Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³¹Hospital Universitario Salamanca, Salamanca, Spain, ³²Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³³Complejo Hospitalario de Zamora, Zamora, Spain, ³⁴Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³⁵Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, ³⁶Hospital Universitario Severo Ochoa, Madrid, Spain, ³⁷Hospital General Universitario de Elche, Elche, Spain, ³⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ³⁹Hospital de Cabueñes, Gijón, Spain, ⁴⁰Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, ⁴¹Hospital San Agustín, Aviles, Spain, ⁴²Hospital Universitario de Valme, Sevilla, Spain, ⁴³Consorci Hospital General Universitari de Valencia, Valencia, Spain, ⁴⁴Hospital Universitario Doctor Negrín, Gran Canaria, Spain, ⁴⁵Hospital Universitario de Castellón, Castellón, Spain, ⁴⁶Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁷Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) may be divided into cranial, and extracranial GCA phenotypes. Tocilizumab (TCZ) has shown efficacy and safety in GCA.Our aim was…
Abstract Number: 1865 • ACR Convergence 2021
Incidence, Prevalence, and Mortality of Chronic Periaortitis: A Population-based Study
Umar Ghaffar¹, Kenneth Warrington², Stephanie Duong¹, Cynthia Crowson³, Michelle Burke¹, Boyd Viers¹, Aaron Potretzke¹, Haraldur Bjarnason¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, ³Mayo Clinic, Eyota, MN
Background/Purpose: Chronic periaortitis is an inflammatory condition that typically involves the infrarenal portion of the abdominal aorta. To date, no epidemiologic studies have been performed…
Abstract Number: L06 • ACR Convergence 2020
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis
Maria C. Cid¹, Sebastian Unizony², Lara Pupim³, Fang Fang⁴, Joseph Pirrello³, Ai Ren⁴, Manoj Samant⁴, Teresa Zhou⁴ and John F Paolini⁴, ¹Hospital Clinic Barcelona, Barcelona, Spain, ²Massachusetts General Hospital, Boston, MA, ³Kiniksa Pharmaceuticals, Lexington, MA, ⁴Kiniksa Pharmaceuticals, Lexington
Background/Purpose: T helper (Th)1 and Th17 lymphocytes play a role in the pathogenesis of giant cell arteritis (GCA). Current treatments (e.g., corticosteroids and tocilizumab) target…
Abstract Number: 0425 • ACR Convergence 2020
MAGIC Syndrome in a Cohort of Patients with Relapsing Polychondritis
Yiming Luo¹, Emily Rose², Keith Sikora³, Kaitlin Quinn⁴, Kristina Wells⁵, Emily Rominger⁵, Wendy Goodspeed⁶, Peter C. Grayson⁷ and Marcela Ferrada⁶, ¹Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ²Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethsda, ³Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ⁴Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ⁵Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ⁶Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome is an extremely rare condition that encompasses symptoms of relapsing polychondritis (RP) and Behcet’s disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].